XACT ACE Robotic System Is Now Available at Lahey Hospital and Medical Center

XACT ACE Robotic System, for use in its leading Interventional Radiology service is availab le at Lahey Hospital and Medical Center.

XACT ACE Robotic System is the world’s first hands-free robotic technology combining advanced image-based procedure planning and navigation with robotic instrument insertion and steering capabilities enabling radiologists to deliver site-specific percutaneous solutions with accuracy, consistency, and efficiency. This benefits patients by enabling physicians to precisely target organs deep inside the body or facilitating the treatment of a disease in a location that is challenging to access.

“By investing in cutting-edge, hands-free robotic technology, we endeavor to further realize our mission of providing superior health care leading to the best possible outcome for every patient,” stated Dr. Christoph Wald, Chair of Radiology at Lahey Hospital & Medical Center. “Lahey Hospital & Medical Center chose to lead as the first hospital in the US offering robotic percutaneous procedures with this device.”

The XACT ACE Robotic system is designed to be compatible with a broad range of imaging modalities capable of delivering various medical instruments to a desired target. Its small footprint and high mobility features enable health care providers to efficiently treat a broad range of patient care needs in multiple areas of the body.

“We have actively participated in clinical research demonstrating the efficacy of XACT Robotic System leading to its approval by the FDA,” stated Dr. Sebastian Flacke, Chief of Interventional Radiology at Lahey Hospital & Medical Center. “Our input has helped to design technology that offers superior clinical outcomes and to help provide safe, cost-effective, and exceptional care to our community.”

“The XACT ACE System is poised to elevate percutaneous radiology standards by delivering enhanced clinical, technical and economic value for the healthcare providers and the patients they serve,” Harel Gadot, Executive Chairman, and President, XACT Robotics stated. “We are excited about the recent transaction with a leading institute such as Lahey Hospital and Medical Center, which allows both the medical center and its patients access to our technology and the multiple benefits it will bring them.”

Dr. Sebastian Flacke has been a consultant and participated in sponsored research with XACT Robotics.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”